New Delhi, May 12, 2023 (GLOBE NEWSWIRE) -- Global companion animal pharmaceuticals market is flourishing because of an increasing awareness about animal health and wellness, rising pet ownership, increasing humanization of pets, and growing adoption of technology advancements in veterinary healthcare.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global companion animal pharmaceuticals market size at USD 34.8 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global companion animal pharmaceuticals market size to grow at a CAGR of 4.42% reaching a value of USD 45.12 billion by 2029. Major growth drivers for the global companion animal pharmaceuticals market include an increasing number of pet adoptions, the rising prevalence of pet diseases, and the growing awareness of the importance of pet health. Also, a surge in demand for pet insurance owing to the rising expenditure on animal health, escalating investments in R&D for animal healthcare, and high rates of pet ownership across the globe are expected to further drive the global market during the period in analysis. However, stringent regulations and lengthy approval processes for animal pharmaceuticals and high costs associated with veterinary drugs and treatments are anticipated to hinder the global market during the forecast period.
Global Companion Animal Pharmaceuticals Market – Overview
A companion animal differs from an assistive animal in that it does not receive any specific training to help a person with a disability. Instead, companion animals provide humans with companionship, entertainment, emotional support, and other functions that humans need from animals. Veterinarians who specialize in companion animals can perform a range of medical services, including treating injuries and illnesses, performing surgeries, administering vaccines, and prescribing medications. They are also responsible for euthanizing animals when necessary. The owners of companion animals are responsible for the animal's well-being, actions, and care. When choosing a companion animal, it is essential to consider the owner's lifestyle, budget, and ability to provide proper care throughout the animal's life. Animal health products, such as feeds, are the most commonly used products for animal healthcare, and this market includes pharmaceuticals and vaccines that improve the health and welfare of animals. Animals obtain nutrition from these products. In recent years, the number of people who own and spend money on companion animals has increased, and pet owners now spend more money per pet than in the past. Pet owners prioritize their pet's health and wellness and expect them to live a healthy life.
Sample Request @ https://www.blueweaveconsulting.com/report/companion-animal-pharmaceuticals-market/report-sample
Impact of COVID-19 on Global Companion Animal Pharmaceuticals Market
COVID-19 pandemic had a dual impact on the global companion animal pharmaceuticals market. On the positive side, with lockdowns and social distancing measures in place, people were spending more time at home and turning to pets for comfort and companionship. It led to an increase in pet ownership and a surge in demand for animal healthcare products and services, including pharmaceuticals. However, on the negative side, the pandemic disrupted global supply chains and manufacturing activities, causing shortages of raw materials and finished products. It led to production delays and increased prices, which affected the profitability of the market players. Moreover, with the focus on human healthcare during the pandemic, veterinary care and services were deprioritized in some regions, leading to a decline in demand for companion animal pharmaceuticals. Despite these challenges, the overall impact of the pandemic on the companion animal pharmaceuticals market was relatively moderate, and the market is expected to recover as the situation normalizes. As people continue to value the companionship of their pets, the demand for animal healthcare products and services is expected to remain robust in the long term.
Please Visit the Press Release: https://www.blueweaveconsulting.com/press-release/global-companion-animal-pharmaceuticals-market-size-set-to-touch-usd-45-12-billion-by-2029
Global Companion Animal Pharmaceuticals Market – By Animal
By animal, the global companion animal pharmaceuticals market is divided into Dogs, Cats, and Horses segments. The dogs segment held the highest share in the global companion animal pharmaceuticals market in 2022. According to Holland Insurance Company Pty. Ltd., India is experiencing an exponential growth in its pet dog population, driven by urbanization and millennials opting for dogs as pets. Also, the growing awareness of pet insurance and animal health importance is expected to boost the market growth. On the other hand, the cats’ segment is projected to grow at the highest compound annual growth rate (CAGR) during the forecast period. Cats are becoming increasingly popular in certain countries like Canada and are preferred over dogs. Additionally, many companies are concentrating on expanding their product range for cats due to their greater susceptibility to diseases when compared to other pets.
Competitive Landscape
Major players operating in the global companion animal pharmaceuticals market include Nestle SA, The Hershey Company, Lindt & Sprungli AG, Mondelez International, Inc., Ferrero Group, Haribo GmbH & Co. KG, Perfetti Van Melle, Russell Stover Chocolates, Wrigley Jr. Company, Ricola AG, Chupa Chups SA, Jelly Belly Candy Company, Lotte Group, Swizzels Matlow Limited, and The Topps Company. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Companion Animal Pharmaceuticals Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Companion Animal Pharmaceuticals Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
Recent Developments
- In November 2022 - Virbac, a United States-based global leading provider of products focusing on companion animals, introduced a new joint supplement for dogs, MOVOFLEX, in Europe.
- In January 2022 - Zoetis obtained approval from the US FDA for its chewable tablets, Simparica Trio (sarolaner, moxidectin, and pyrantel), which now includes a new label indication for the prevention of Borrelia burgdorferi infections in dogs.
Scope of the Report
| Attributes | Details |
| Years Considered | Historical Data – 2019–2022 |
| Base Year – 2022 | |
| Estimated Year – 2023 | |
| Forecast Period – 2023–2029 | |
| Facts Covered | Revenue in USD Billion |
| Market Coverage | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Product/ Service Segmentation | Animal, Route of Administration, Product |
| Key Players | Zoetis Inc., Merck Animal Health, Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, Bayer AG, Virbac, Dechra Pharmaceuticals PLC, Vetoquinol SA, Ceva Santé Animale, Kindred Biosciences, Inc., Norbrook, IDEXX Laboratories, Inc., Animalcare Group plc, Neogen Corporation, Heska Corporation |
By Animal
- Dogs
- Cats
- Horses
By Route of Administration
- Oral
- Injectable
- Topical
By Product
- Antibiotics
- Anti-Inflammatory
- Parasiticides
- Vaccines
By Region
- North America
- Europe
- Asia Pacific (APAC)
- Latin America
- Middle East and Africa (MEA)
Please Find Below Some related Topics:
- Anti-Hair Loss Medicine Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029
- Minimal Residual Disease Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029
- Cell Culture Consumables and Equipment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029
- Perinatal Infections Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029
- Adrenocorticotropic Hormone (ACTH) Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029
About Us
BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.
Contact Us:
BlueWeave Consulting & Research Pvt. Ltd
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662
info@blueweaveconsulting.com
https://www.blueweaveconsulting.com/
https://www.linkedin.com/company/blueweaveconsulting/
